Participants With Normal Hepatic Function clinical trials

Explore recruiting participants with normal hepatic function clinical trials.

Recruiting participants with normal hepatic function studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Participants With Normal Hepatic Function trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 given as an oral single 50 mg dose in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.

Bulgaria, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic function

Spain, Portugal

Human Pharmacology (Phase I)- Other EU CTIS Study details

Participants With Normal Hepatic Function trials by city

Participants With Normal Hepatic Function clinical trials

Recruiting participants with normal hepatic function studies right now

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function

A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function

A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment

Also recruiting in Europe

A multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 given as an oral single 50 mg dose in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.

A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic function

Participants With Normal Hepatic Function trials by city

Other conditions